tocilizumab
Cold Chain RequiredFDA Approved, EMA Approved
Description
Tocilizumab is a humanized monoclonal antibody that inhibits interleukin-6 (IL-6) receptor signaling. It is approved for giant cell arteritis and has shown efficacy in other forms of vasculitis and autoimmune conditions. The drug blocks both soluble and membrane-bound IL-6 receptors, reducing inflammatory responses.
Indications & Therapeutic Use
giant cell arteritis, medium-vessel vasculitis, systemic inflammatory conditions
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
tocilizumab
| Generic Name | tocilizumab |
| Brands | 1 brand available |
| Active Ingredient | tocilizumab |
| Drug Class | giant cell arteritis |
| Manufacturer | Genentech/Roche |
| Dosage Forms | IV infusion 20mg/mL; subcutaneous injection 162mg/0.9mL |
| Medical Code | L04AC07 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT01791153 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes